We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

47 hedge funds and large institutions have $126M invested in Ibere Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

5% more capital invested

Capital invested by funds: $120M → $126M (+$6.18M)

2% less funds holding

Funds holding: 48 → 47 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
47
Holders Change
-1
Holders Change %
-2.08%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HSBC Holdings
HSBC Holdings
United Kingdom
+$3.25M
2
AC
Aristeia Capital
Connecticut
+$2.5M
3
WCMNY
Westchester Capital Management (New York)
New York
+$2.44M
4
GCL
Glazer Capital LLC
New York
+$2.44M
5
HIM
HGC Investment Management
Ontario, Canada
+$490K

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$2.44M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.25M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$529K
5
PI
PEAK6 Investments
Illinois
-$496K
Name Holding Trade Value Shares
Change 		Change in
Stake
CF
26
Cantor Fitzgerald
New York
$1.13M – – –
Walleye Capital
27
Walleye Capital
New York
$1.11M – – –
FTCM
28
Fir Tree Capital Management
New York
$828K -$1.63K -163 -0.2%
Walleye Trading
29
Walleye Trading
New York
$807K – – –
WA
30
Whitebox Advisors
Minnesota
$759K – – –
CSS
31
Cubist Systematic Strategies
Connecticut
$752K +$40.8K +4,077 +6%
WRBC
32
W.R. Berkley Corp
Connecticut
$698K +$4K +400 +0.6%
Janus Henderson Group
33
Janus Henderson Group
United Kingdom
$534K -$529K -52,917 -50%
LCM
34
Lynwood Capital Management
Ontario, Canada
$519K – – –
Goldman Sachs
35
Goldman Sachs
New York
$515K – – –
HIM
36
HGC Investment Management
Ontario, Canada
$495K +$490K +49,023 New
DMKJ
37
David M. Knott Jr
$363K – – –
SAM
38
Silverback Asset Management
North Carolina
$303K – – –
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$296K – – –
WAM
40
Wolverine Asset Management
Illinois
$291K +$289K +28,841 New
Capstone Investment Advisors
41
Capstone Investment Advisors
New York
$252K – – –
ETH
42
Exos TFP Holdings
New York
$230K +$228K +22,792 New
DIG
43
DeepCurrents Investment Group
New York
$179K – – –
DFCM
44
Dark Forest Capital Management
Puerto Rico
$157K – – –
RCM
45
Robinson Capital Management
Michigan
$96.4K – – –
CS
46
Clear Street
New York
$16K +$15.4K +1,543 New
UBS Group
47
UBS Group
Switzerland
$5.49K -$15.4K -1,541 -74%
CAC
48
Cowen and Company
New York
– -$2.44M -246,290 Closed
Citadel Advisors
49
Citadel Advisors
Florida
– -$2.26M -227,718 Closed
PI
50
PEAK6 Investments
Illinois
– -$496K -50,000 Closed
1
2
3

IBER Hedge Fund Activity: Q4 2022 in Review

47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q4 2022, worth a combined $126M — up 5.2% from $120M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IBER and 6 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.

The largest buyer was HSBC Holdings, opening a new position worth an estimated $3.25M. The largest seller was Cowen and Company, exiting entirely with an estimated $2.44M sold.

  • 47 institutional investors held Ibere Pharmaceuticals (IBER) as of Q4 2022, down from 48 in Q3 2022.
  • Funds reported $126M of Ibere Pharmaceuticals stock for Q4 2022, up 5.2% quarter-over-quarter.
  • 6 funds opened new Ibere Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of -1 holder.
  • The largest Ibere Pharmaceuticals buyer in Q4 2022 was HSBC Holdings, an estimated $3.25M added.
  • The largest Ibere Pharmaceuticals seller in Q4 2022 was Cowen and Company, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2022.